Aimovig® (erenumab-aooe) Prior Authorization (PA) Checklist

Your patient's health plan may require a PA for Aimovig®. This checklist may help you organize specific information about your patient's diagnosis and treatment history to complete an Aimovig® PA. Please note that PA criteria may vary by health plan, and be sure to confirm the PA criteria and documentation required by your patient's insurer.

Patient name: _____ DOB: _____ Date of service: _____ Insurance plan: _____

Physician: _____ ☐ Neurologist ☐ General practitioner ☐ Other _____

Document baseline: _____ migraine days per month

1 Diagnosis[1,2]

☐ Episodic migraine ☐ Chronic migraine

Diagnosis code

EXAMPLES OF MIGRAINE DIAGNOSIS CODES*			
G43.00	Migraine without aura, not intractable	G43.01	Migraine without aura, intractable
G43.10	Migraine with aura, not intractable	G43.11	Migraine with aura, intractable
G43.70	Chronic migraine without aura, not intractable	G43.71	Chronic migraine without aura, intractable
G43.80	Other migraine, not intractable	G43.81	Other migraine, intractable
G43.90	Migraine, unspecified, not intractable	G43.91	Migraine, unspecified, intractable

*The sample diagnosis codes are informational and not intended to be directive or a guarantee of reimbursement and include potential codes that would include FDA-approved indications for Aimovig®. For a full list of ICD-10 codes, please consult the most recent version of the ICD-10.

2 Aimovig® dose[3]

☐ Aimovig® 70 mg/mL ☐ Aimovig® 140 mg/mL

3 Medication history[1,4-6]

Previous prescription therapies received for migraine, including duration of treatment, reason for discontinuation, and associated contraindications

☐ Patient has been treated with a CGRP pathway antagonist as preventive or acute therapy. (Circle preventive or acute)
Please specify drug name, dose, duration, and reason for discontinuation: _____

Preventive therapy

DRUG CATEGORY	DRUG NAME	TREATMENT DURATION	REASON FOR DISCONTINUATION
☐ Antiepileptics (eg, divalproex sodium, topiramate)			☐ Inadequate response ☐ Intolerance
☐ Beta blockers (eg, propranolol, metoprolol, timolol)			☐ Inadequate response ☐ Intolerance
☐ Antidepressants (eg, amitriptyline, venlafaxine)			☐ Inadequate response ☐ Intolerance
☐ ACE inhibitors (eg, lisinopril)			☐ Inadequate response ☐ Intolerance
☐ Angiotensin receptor blockers (eg, candesartan)			☐ Inadequate response ☐ Intolerance
☐ Calcium channel blockers (eg, nimodipine)			☐ Inadequate response ☐ Intolerance

List contraindications to any medications listed above: _____

Acute therapy

DRUG CATEGORY	DRUG NAME	TREATMENT DURATION	REASON FOR DISCONTINUATION	OVERUSE	CONTRAINDICATION
☐ Triptans (eg, sumatriptan)			☐ Inadequate response ☐ Intolerance	☐	☐

ACE=angiotensin-converting enzyme; CGRP=calcitonin gene-related peptide; ICD-10=International Classification of Diseases, Tenth Edition.

INDICATION

Aimovig® (erenumab-aooe) is indicated for the preventive treatment of migraine in adults.

IMPORTANT SAFETY INFORMATION

Contraindication: Aimovig® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema.

Please see additional Important Safety Information on the next page.

Aimovig® PA Checklist continued on next page.

aimovig® (erenumab-aooe) injection 70 mg/mL • 140 mg/mL

4 Additional treatment considerations[7,8]

Select any that apply:

- ☐ Takes OTC medication as acute therapy. Please specify: _____
- ☐ Patient has been evaluated for medication overuse headache (MOH)

Please list other medications/nonpharmacological therapies used to treat migraine: _____

OTC=over-the-counter.

5 Reauthorization[4,8]

Has this patient already been approved under this plan? If yes, document the following:

- ☐ Patient has experienced a reduction in monthly migraine days
- ☐ Decrease in use of acute migraine medications. Please specify: _____

For additional support and resources, scan the QR code

Please note: This checklist is informational and provided as a courtesy only. It is not intended to be a comprehensive resource or reflect the specific requirements of any health plan. This checklist is not intended to be directive or a guarantee of coverage, and should not be a substitute for an independent clinical decision. It is the duty of the healthcare provider to understand individual patient considerations and use their own judgment and clinical decision-making when determining a particular patient's diagnosis and treatment.

IMPORTANT SAFETY INFORMATION

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported with Aimovig® in post marketing experience. Most reactions were not serious and occurred within hours of administration, although some occurred more than one week after administration. If a serious or severe reaction occurs, discontinue Aimovig® and initiate appropriate therapy.

Constipation with Serious Complications: Constipation with serious complications has been reported following the use of Aimovig® in the postmarketing setting. There were cases that required hospitalization, including cases where surgery was necessary. The onset of constipation was reported after the first dose in a majority of these cases, but patients also reported later on in treatment. Aimovig® was discontinued in most reported cases. Constipation was one of the most common (up to 3%) adverse reactions reported in clinical studies.

Monitor patients treated with Aimovig® for severe constipation and manage as clinically appropriate. Concurrent use of medications associated with decreased gastrointestinal motility may increase the risk for more severe constipation and the potential for constipation-related complications.

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of Aimovig® in the postmarketing setting. Many of the patients had pre-existing hypertension or risk factors for hypertension. There were cases requiring pharmacological treatment and, in some cases, hospitalization. Hypertension may occur at any time during treatment but was most frequently reported within seven days of dose administration. In the majority of the cases, the onset or worsening of hypertension was reported after the first dose. Aimovig® was discontinued in many of the reported cases.

Monitor patients treated with Aimovig® for new-onset hypertension, or worsening of pre-existing hypertension, and consider whether discontinuation of Aimovig® is warranted if evaluation fails to establish an alternative etiology.

Adverse Reactions: The most common adverse reactions in clinical studies (≥ 3% of Aimovig®-treated patients and more often than placebo) were injection site reactions and constipation.

Click here for Aimovig® full Prescribing Information.

References: 1. UnitedHealthcare website. UnitedHealthcare pharmacy: clinical pharmacy programs. https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/a-g/PA-Med-Nec-Aimovig.pdf. Accessed July 12, 2022. **2.** Centers for Medicare & Medicaid website. ICD-10-CM tabular list of diseases and injuries. https://www.cms.gov/files/zip/2022-code-tables-tabular-and-index-updated-02012022.zip. Accessed August 4, 2022. **3.** Aimovig® (erenumab-aooe) prescribing information, Amgen. **4.** BlueCross BlueShield website. Federal Employee Program: Aimovig (erenumab-aooe) injection. https://www.caremark.com/portal/asset/FEP_Criteria_Aimovig.pdf. Accessed July 12, 2022. **5.** Cigna website. Prior Authorization: Calcitonin Gene-Related Peptide Inhibitors – Aimovig®. https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_331_coveragepositioncriteria_calcitonin_gene-related_peptide_inhibitors_aimovig_pa.pdf. Accessed July 12, 2022. **6.** Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults. *Neurology*. 2012;78:1337-1345. **7.** American Migraine Foundation website. Over-the-counter migraine medication. www.americanmigrainefoundation.org/resource-library/otc-migraine-treatment/. Accessed August 3, 2022. **8.** OptumRx website. Aimovig™ & Ajovy™ Prior Authorization Request Form. https://professionals.optumrx.com/content/dam/optum3/professional-optumrx/resources/pdfs/ORxCommForms/Aimovig-Ajovy_Comm.pdf. Accessed July 12, 2022.

AMGEN®

aimovig® (erenumab-aooe) injection 70 mg/mL • 140 mg/mL